Parkinson’s Disease

NeoNeuron engages in collaborative partnerships and contract services in an OLAW-assured and AAALAC-accredited state-of-the-art animal facility in California.

NeoNeuron has decades of experience in animal models of Parkinson’s disease (PD) generated by the use of neurotoxins MPTP or 6-OHDA or by viral vector-mediated overexpression of genes involved in the pathogenesis of PD.

We work with the current gold standard non-human primate (NHP) model of PD. The MPTP-treated animals develop authentic Parkinsonian syndrome and closely mimic the biochemical, neuroanatomical, physiological and functional characteristics of humans, Including the long-term side effects of levodopa pharmacotherapy, dyskinesias. This model is relevant for establishing the safety, route and mode of cells, genes or drug candidates administration, pharmacokinetics and dose-range efficacy to support IND filing for clinical trials.